{
  "case_id": "EI14-19068",
  "year": 2014,
  "patient_info": {
    "age_range": "41 to 50",
    "gender": "Female"
  },
  "diagnosis": "Immuno Disorders",
  "secondary_conditions": [],
  "complications": [],
  "symptoms": [],
  "treatment_category": "Pharmacy",
  "treatment_subcategory": "Other",
  "treatments_requested": [
    {
      "name": "Benlysta",
      "drug_type": "experimental",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": "Antibody inhibitor of the B-lymphocyte stimulator"
    }
  ],
  "treatments_tried_but_failed": [],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [],
  "is_denial_upheld": false,
  "issues_considered": [
    "medical_necessity",
    "plan_coverage"
  ],
  "other_issues": null,
  "guidelines_support": true,
  "guidelines_not_support": false,
  "guidelines_details": "Benlysta is FDA approved for systemic lupus erythematosus.",
  "soc_support": true,
  "soc_not_support": false,
  "soc_details": "Benlysta has been demonstrated to be safe and effective in at least two randomized clinical trials.",
  "study_support": true,
  "study_details": [
    {
      "study_name": "Randomized Clinical Trials",
      "study_authors": "Thanou-Stavraki and Sawalha",
      "key_findings": "Benlysta is safe and effective compared with placebo in the treatment of systemic lupus erythematosus."
    }
  ],
  "key_questions": [
    "medical_necessity",
    "plan_coverage"
  ],
  "expedited": false,
  "rationale": "Benlysta is likely to be more beneficial for treatment of this patient\u2019s medical condition than any available standard therapy.",
  "reviewer_credentials": null
}